SynthesisBlood2011
EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.
Synthesis in Blood, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
107 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Breast implant-associated anaplastic large cell lymphoma: a systematic review of the literature and mini-meta analysis.Current hematologic malignancy reports · 2013Pooled it
- Breast implant-associated ALCL: a unique entity in the spectrum of CD30+ lymphoproliferative disorders.The oncologist · 2013Pooled it
- Phase I/II clinical trial of brentuximab vedotin for pretreated Japanese patients with CD30-positive cutaneous T-cell lymphoma.The Journal of dermatology · 2024Trial
- Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data.Blood advances · 2021Trial
- Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis: An Analysis of Phase 2 Results.JAMA dermatology · 2017Trial
- Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2015Trial
- Oral Relapsing Lymphomatoid Papulosis: A Case Report.Clinical case reports · 2026Article
- Severe lymphomatoid papulosis with lymphadenopathy, facial involvement, and a pathogenic STAT3 variant.JAAD case reports · 2026Article
- Lymphomatoid papulosis type D with γδ phenotype evolving from pityriasis lichenoides in a pediatric patient.JAAD case reports · 2026Article
- Primary Cutaneous Anaplastic Large Cell Lymphoma: A Review of Diagnosis and Treatment for the General Oncologist.Cancers · 2026Review
- Article
- Article
- Primary Cutaneous B-Cell Lymphomas: An Updated Portrait of Classification, Biology, and Clinical Management.European journal of haematology · 2026Review
- Pediatric lymphomatoid papulosis: a broad clinicopathologic spectrum including rare variants in a single-center case series.Frontiers in medicine · 2026Article
- Primary cutaneous anaplastic large cell lymphoma: Clinical response with low dose brentuximab vedotin on a patient receiving hemodialysis.JAAD case reports · 2025Article
- Topical Chlormethine Gel in the Treatment of Lymphomatoid Papulosis: A Case Report and Literature Review.Journal of clinical medicine · 2025Article
- Article
- Molecular Insights into the Diagnosis of Anaplastic Large Cell Lymphoma: Beyond Morphology and Immunophenotype.International journal of molecular sciences · 2025Review
- Retrospective Evaluation of Clinical and Follow-Up Outcomes in Primary Cutaneous CD30Turkish journal of haematology : official journal of Turkish Society of Haematology · 2025Article
- OX40-OX40L Axis in Cutaneous T-Cell Lymphomas: Pathogenic, Prognostic, and Potential Therapeutic Perspectives.Biomolecules · 2025Review
47 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary cutaneous CD30(+) lymphoproliferative disorders (CD30(+) LPDs) are the second most common form of cutaneous T-cell lymphomas and include lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Despite the anaplastic cytomorphology of tumor cells that suggest an aggressive course, CD30(+) LPDs are characterized by an excellent prognosis. Although a broad spectrum of therapeutic strategies has been reported, these have been limited mostly to small retrospective cohort series or case reports, and only very few prospective controlled or multicenter studies have been performed, which results in a low level of evidence for most therapies. The response rates to treatment, recurrence rates, and outcome have not been analyzed in a systematic review. Moreover, international guidelines for staging and treatment of CD30(+) LPDs have not yet been presented. Based on a literature analysis and discussions, recommendations were elaborated by a multidisciplinary expert panel of the Cutaneous Lymphoma Task Force of the European Organization for Research and Treatment of Cancer, the International Society for Cutaneous Lymphomas, and the United States Cutaneous Lymphoma Consortium. The recommendations represent the state-of-the-art management of CD30(+) LPDs and include definitions for clinical endpoints as well as response criteria for future clinical trials in CD30(+) LPDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.